484 related articles for article (PubMed ID: 11712793)
21. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT.
Tsai CS; Chang TC; Lai CH; Tsai CC; Ng KK; Hsueh S; Yen TC; Hong JH
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1506-12. PubMed ID: 15050330
[TBL] [Abstract][Full Text] [Related]
22. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
[TBL] [Abstract][Full Text] [Related]
23. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
[TBL] [Abstract][Full Text] [Related]
24. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
[TBL] [Abstract][Full Text] [Related]
26. Role of 18F-FDG PET/CT in detecting pelvic lymph-node metastases in patients with early-stage uterine cervical cancer: comparison with MRI findings.
Lv K; Guo HM; Lu YJ; Wu ZX; Zhang K; Han JK
Nucl Med Commun; 2014 Dec; 35(12):1204-11. PubMed ID: 25222911
[TBL] [Abstract][Full Text] [Related]
27. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
28. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.
Yildirim Y; Sehirali S; Avci ME; Yilmaz C; Ertopcu K; Tinar S; Duman Y; Sayhan S
Gynecol Oncol; 2008 Jan; 108(1):154-9. PubMed ID: 17945337
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings.
Inubashiri E; Hata K; Kanenishi K; Shiota A; Ohno M; Yamamoto Y; Nishiyama Y; Ohkawa M; Hata T
J Obstet Gynaecol Res; 2009 Feb; 35(1):26-34. PubMed ID: 19215544
[TBL] [Abstract][Full Text] [Related]
30. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutch DG; Powell MA; Grigsby PW
J Clin Oncol; 2010 Apr; 28(12):2108-13. PubMed ID: 20308664
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.
Chang WC; Hung YC; Lin CC; Shen YY; Kao CH
Cancer Invest; 2004; 22(2):180-4. PubMed ID: 15199599
[TBL] [Abstract][Full Text] [Related]
32. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
33. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Mori A; Doi R; Ikai I; Uemoto S
Surgery; 2008 Jun; 143(6):769-77. PubMed ID: 18549893
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.
Tsai CS; Lai CH; Chang TC; Yen TC; Ng KK; Hsueh S; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):477-84. PubMed ID: 19464824
[TBL] [Abstract][Full Text] [Related]
35. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area.
Boughanim M; Leboulleux S; Rey A; Pham CT; Zafrani Y; Duvillard P; Lumbroso J; Haie-Meder C; Schlumberger M; Morice P
J Clin Oncol; 2008 May; 26(15):2558-61. PubMed ID: 18487573
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
37. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
[TBL] [Abstract][Full Text] [Related]
38. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
39. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
[TBL] [Abstract][Full Text] [Related]
40. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
